iShares iBoxx $ Inv Grade Corporate Bond ETF vs Tenet Healthcare Corporation — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.36 (market cap $28.50B), while Tenet Healthcare Corporation trades at $265.7 (market cap $20.98B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is the larger of the two by market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Tenet Healthcare Corporation for 15 Days on average.
| LQD | THC | |
|---|---|---|
Market Cap | $28.50B | $20.98B |
Volume | 37,320,110 | 428,008 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $280.77 |
52-Week Low | $101.83 | $161.37 |
Typical Hold Time | 125 Days | 15 Days |
Enterprise Value | — | $32.06B |
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.39 with a slight 0.26% daily gain amid a challenging bond market environment. The ETF faces bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September (Defense World, 2026-10-01) and concerns about investment-grade corporate bonds as Treasury yields hit multi-decade highs.
The outlook remains cautious with rising bond yields creating headwinds for corporate bond ETFs. While LQD offers a 4.8% yield with high-quality portfolio exposure, the weak investment thesis noted by Seeking Alpha (2026-09-22) and substantial short interest growth suggest near-term pressure. Investors should monitor Fed policy decisions and corporate bond market stability for directional cues.
Tenet Healthcare (THC) trades at $265.42, up 2.15% today, with a bullish technical signal from moving averages and strong support near $257. The company shows robust fundamentals, including a 53.31% ROE and consistent earnings beats, with Q3 2026 results due October 29. Revenue growth is supported by higher revenue per case despite softer surgical volumes, as noted by Zacks on September 24, 2026.
The outlook is positive, with an 81.25% analyst buy rating and a $283.36 consensus price target implying ~7% upside. Risks include sustainability of capital returns amid growth investments and potential volume pressures, but solid cash flow and valuation metrics like a 10.07 P/E suggest room for appreciation if execution continues.
Trailing returns across standard periods
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →